Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Metrics to compare | OCC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOCCPeersSector | |
---|---|---|---|---|
P/E Ratio | −27.0x | −2.9x | −0.7x | |
PEG Ratio | 2.16 | −0.07 | 0.00 | |
Price/Book | 42.7x | 2.1x | 2.6x | |
Price / LTM Sales | 36.4x | 8.8x | 3.2x | |
Upside (Analyst Target) | - | 266.2% | 44.5% | |
Fair Value Upside | Unlock | −2.0% | 6.6% | Unlock |